UK’s NICE Faults BMS/AstraZeneca’s Forxiga On Both Clinical, Cost-Effectiveness Issues
This article was originally published in The Pink Sheet Daily
Executive Summary
NICE has provisionally rejected Forxiga for type 2 diabetes, but hints at a recommendation for triple, if not dual, therapy; a quick revision should keep the product ahead of the competition.